Cargando…

Salvaging Detection of Early-Stage Ovarian Malignancies When CA125 Is Not Informative

Background: Ovarian cancer is the deadliest gynecologic cancer, with no recommended screening test to assist with early detection. Cancer antigen 125 (CA125) is a serum biomarker commonly used by clinicians to assess preoperative cancer risk, but it underperforms in premenopausal women, early-stage...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dunton, Charles J., Hutchcraft, Megan L., Bullock, Rowan G., Northrop, Lesley E., Ueland, Frederick R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8394730/ https://www.ncbi.nlm.nih.gov/pubmed/34441373 http://dx.doi.org/10.3390/diagnostics11081440

Ejemplares similares

Multivariate Index Assay Is Superior to CA125 and HE4 Testing in Detection of Ovarian Malignancy in African-American Women
por: Dunton, Charles, et al.
Publicado: (2019)

The Serum CA-125 Concentration Data Assists in Evaluating CT Imaging Information When Used to Differentiate Borderline Ovarian Tumor from Malignant Epithelial Ovarian Tumors
por: Shin, Ji-Eun, et al.
Publicado: (2011)

Analytical Validation of a Deep Neural Network Algorithm for the Detection of Ovarian Cancer
por: Reilly, Gerard, et al.
Publicado: (2022)

Symptoms, CA125 and HE4 for the preoperative prediction of ovarian malignancy in Brazilian women with ovarian masses
por: Pitta, Denise da Rocha, et al.
Publicado: (2013)

Predictive equation of metastasis in patients with malignant ovarian epithelial tumors with the Ca-125 marker
por: Sánchez Vega, Juan Fernando, et al.
Publicado: (2018)

THE ROLE OF SALIVARY AND SERUM CA125 AND ROUTINE BLOOD TESTS IN PATIENTS WITH OVARIAN MALIGNANCIES
por: Vuković, Ante, et al.
Publicado: (2021)

Comparison of HE4, CA125, and Risk of Ovarian Malignancy Algorithm in the Prediction of Ovarian Cancer in Korean Women
por: Cho, Hye Yon, et al.
Publicado: (2015)

Combined score of pretreatment platelet count and CA125 level (PLT-CA125) stratified prognosis in patients with FIGO stage IV epithelial ovarian cancer
por: Chen, Jie-Ping, et al.
Publicado: (2019)

HE4 and CA125 as a diagnostic test in ovarian cancer: prospective validation of the Risk of Ovarian Malignancy Algorithm
por: Van Gorp, T, et al.
Publicado: (2011)

CA125 in ovarian tumour tissue at second laparotomy.
por: Maughan, T. S., et al.
Publicado: (1989)

HE4, CA-125, and cystic ovarian mass
por: Wiwanitkit, Viroj
Publicado: (2012)

CA125 and Ovarian Cancer: A Comprehensive Review
por: Charkhchi, Parsa, et al.
Publicado: (2020)

Preoperative LMR and Serum CA125 Level as Risk Factors for Advanced Stage of Ovarian Cancer
por: Tang, Ying, et al.
Publicado: (2021)

A comparison of CA125, HE4, risk ovarian malignancy algorithm (ROMA), and risk malignancy index (RMI) for the classification of ovarian masses
por: Anton, Cristina, et al.
Publicado: (2012)

Longitudinal monitoring of CA125 levels provides additional information about survival in ovarian cancer
por: Gupta, Digant, et al.
Publicado: (2010)

MUTYH as an Emerging Predictive Biomarker in Ovarian Cancer
por: Hutchcraft, Megan L., et al.
Publicado: (2021)

CA-125 and risk of malignancy index for screening for malignancy in fertile aged females with ovarian cyst, which is more cost effectiveness?
por: Wiwanitkit, Viroj
Publicado: (2013)

Deciphering the Molecular Nature of Ovarian Cancer Biomarker CA125
por: Weiland, Florian, et al.
Publicado: (2012)

The power of the Risk of Ovarian Malignancy Algorithm considering menopausal status: a comparison with CA 125 and HE4
por: Han, Kyung Hee, et al.
Publicado: (2019)

Clinical significance of serum CA125 in diffuse malignant mesothelioma
por: Cheng, Xu, et al.
Publicado: (2016)

CA19-9 as a marker for ovarian cancer: alone and in comparison with CA125.
por: Canney, P. A., et al.
Publicado: (1985)

The Value of CA 125 and CA72-4 in Management of Patients with Epithelial Ovarian Cancer
por: Fayed, Salah T., et al.
Publicado: (1998)

Tumour-associated trypsin inhibitor (TATI) and cancer antigen 125 (CA 125) in mucinous ovarian tumours.
por: Mogensen, O., et al.
Publicado: (1990)

Evaluation of various kinetic parameters of CA-125 in patients with advanced-stage ovarian cancer undergoing neoadjuvant chemotherapy
por: Lee, Yong Jae, et al.
Publicado: (2018)

Trial of isotretinoin and calcitriol monitored by CA 125 in patients with ovarian cancer.
por: Rustin, G. J., et al.
Publicado: (1996)

Combination of CA125 and RECAF biomarkers for early detection of ovarian cancer
por: Tcherkassova, Janneta, et al.
Publicado: (2011)

TB Peritonitis Mistaken for Ovarian Carcinomatosis Based on an Elevated CA-125
por: Boss, Joseph D., et al.
Publicado: (2012)

Is CA125 useful in monitoring patients with platinum-resistant ovarian cancer?
por: Rustin, G. J. S., et al.
Publicado: (2016)

Exosomal CA125 as A Promising Biomarker for Ovarian Cancer Diagnosis
por: Chen, Zhixiang, et al.
Publicado: (2020)

Combined Preoperative LMR and CA125 for Prognostic Assessment of Ovarian Cancer
por: Tang, Ying, et al.
Publicado: (2020)

VCAM-1 complements CA-125 in detecting recurrent ovarian cancer
por: Song, Jin, et al.
Publicado: (2023)

Ligand-based adoptive T cell targeting CA125 in ovarian cancer
por: Zhao, Haihong, et al.
Publicado: (2023)

Serum CA19‐9, CA‐125 and CEA as tumor markers for mucinous ovarian tumors
por: Lertkhachonsuk, Arb‐aroon, et al.
Publicado: (2020)

The prognostic value of pretreatment CA-125 levels and CA-125 normalization in ovarian clear cell carcinoma: a two-academic-institute study
por: Bai, Huimin, et al.
Publicado: (2016)

Clinical utility of CA-125 in the management of uterine carcinosarcoma
por: Matsuo, Koji, et al.
Publicado: (2018)

Efficacy of HE4, CA125, Risk of Malignancy Index and Risk of Ovarian Malignancy Index to Detect Ovarian Cancer in Women with Presumed Benign Ovarian Tumours: A Prospective, Multicentre Trial
por: Dochez, Vincent, et al.
Publicado: (2019)

CA125, CEA, CA19-9, and Heteroploid Cells in Ascites Fluid May Help Diagnose Peritoneal Carcinomatosis in Patients with Gastrointestinal and Ovarian Malignancies
por: Deng, Lin, et al.
Publicado: (2020)

An Antibody‐Tumor Model for the Targeting of CA125‐producing Gynecologic Malignancies
por: Saga, Tsuneo, et al.
Publicado: (1990)

Clinical Applicability of Tissue Polypeptide Antigen and CA-125 in Gynecological Malignancies
por: Schröder, Lars, et al.
Publicado: (2023)

Different Levels of CEA, CA153 and CA125 in Milk and Benign and Malignant Nipple Discharge
por: Zhao, Song, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_oobuuum32ud8ka0ur1m7g54i21